Iecure Launches With $50 Million Series A Financing To Develop In Vivo Gene Insertion Approaches For Devastating Diseases
Iecure Launches With $50 Million Series A Financing To Develop In Vivo Gene Insertion Approaches For Devastating Diseases
09/09/21, 11:09 AM
Location
philadelphiaMoney raised
$50 million
Round Type
series a
iECURE (pronounced EE-ah-cure), a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet need, today announced it has closed a $50 million Series A financing led by Versant Ventures and OrbiMed Advisors. The funds will be used to advance iECURE’s pipeline of up to 13 programs, all of which benefit from gene editing and in vivo delivery approaches being developed in the laboratory of James Wilson, M.D., Ph.D., of the University of Pennsylvania Gene Therapy Program (GTP).
Company Info
Location
philadelphia, pennsylvania, united states
Additional Info
iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet need. We are advancing our pipeline in close partnership with the world-class translational engine at the University of Pennsylvania’s Gene Therapy Program. Using in vivo editing, our methods focus on inserting functioning genes into patients’ genomes, which offers long-term, stable expression of those genes. With our team’s proven track record, as well as the University of Pennsylvania’s deep expertise and translational genetic medicine engine, reversing the course of these devastating diseases is now within reach.